<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The development of immunodeficient mouse <z:e sem="disease" ids="C1520166" disease_type="Experimental Model of Disease" abbrv="">xenograft models</z:e> has greatly facilitated the investigation of some human <z:e sem="disease" ids="C0376544" disease_type="Neoplastic Process" abbrv="">hematopoietic malignancies</z:e>, but application of this approach to the <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> (MDSs) has proven difficult </plain></SENT>
<SENT sid="1" pm="."><plain>We now show that cells from most <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> patients (including <z:hpo ids='HP_0000001'>all</z:hpo> subtypes) repopulate nonobese diabetic-severe combined immunodeficient (scid)/scid-beta2 microglobulin null (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">NOD</z:e>/<z:mp ids='MP_0002536'>SCID</z:mp>-beta2m(-/-)) mice at least transiently and produce abnormal differentiation patterns in this model </plain></SENT>
<SENT sid="2" pm="."><plain><z:mpath ids='MPATH_458'>Normal</z:mpath> marrow transplants initially produce predominantly erythroid cells and later predominantly B-lymphoid cells in these mice, whereas most <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> samples produced predominantly granulopoietic cells </plain></SENT>
<SENT sid="3" pm="."><plain>In 4 of 4 MDS cases, the regenerated cells showed the same clonal markers (<z:mp ids='MP_0004027'>trisomy</z:mp> 8, n = 3; and 5q-, n = 1) as the original sample and, in one instance, regenerated <z:mp ids='MP_0004027'>trisomy</z:mp> 8(+) B-lymphoid as well as myeloid cells were identified </plain></SENT>
<SENT sid="4" pm="."><plain>Interestingly, the enhanced growth of <z:mpath ids='MPATH_458'>normal</z:mpath> marrow obtained in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">NOD</z:e>/<z:mp ids='MP_0002536'>SCID</z:mp>-beta2m(-/-) mice engineered to produce human interleukin-3, granulocyte-macrophage colony-stimulating factor, and Steel factor was seen only with 1 of 7 MDS samples </plain></SENT>
<SENT sid="5" pm="."><plain>These findings support the concept that human <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> originates in a transplantable multilineage hematopoietic stem cell whose genetic alteration may affect patterns of differentiation and responsiveness to hematopoietic growth factors </plain></SENT>
<SENT sid="6" pm="."><plain>They also demonstrate the potential of this new murine xenotransplant model for future investigations of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
</text></document>